Aurinia Pharmaceuticals Inc.
AUPH · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $1 | $3 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $1 | $1 | $3 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 34% | 31% | 193.9% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 88% | 91.9% | 95.8% | 97.6% |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 13.5% | -35.9% | -77.3% | -389.1% |
| Net Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 2.4% | -44.5% | -80.7% | -396.8% |
| EPS Diluted | 0.039 | -0.54 | -0.76 | -1.4 |
| % Growth | 107.3% | 28.9% | 45.7% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | -$0 | -$0 | -$0 |